"Fluoxetine" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
The first highly specific serotonin uptake inhibitor. It is used as an antidepressant and often has a more acceptable side-effects profile than traditional antidepressants.
| Descriptor ID |
D005473
|
| MeSH Number(s) |
D02.092.831.280
|
| Concept/Terms |
Fluoxetine- Fluoxetine
- Fluoxetin
- N-Methyl-gamma-(4-(trifluoromethyl)phenoxy)benzenepropanamine
|
Below are MeSH descriptors whose meaning is more general than "Fluoxetine".
Below are MeSH descriptors whose meaning is more specific than "Fluoxetine".
This graph shows the total number of publications written about "Fluoxetine" by people in this website by year, and whether "Fluoxetine" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1995 | 1 | 0 | 1 |
| 1997 | 0 | 4 | 4 |
| 1998 | 3 | 1 | 4 |
| 1999 | 3 | 0 | 3 |
| 2000 | 1 | 0 | 1 |
| 2003 | 1 | 0 | 1 |
| 2004 | 1 | 0 | 1 |
| 2005 | 3 | 0 | 3 |
| 2006 | 1 | 0 | 1 |
| 2007 | 0 | 2 | 2 |
| 2008 | 1 | 0 | 1 |
| 2009 | 0 | 1 | 1 |
| 2010 | 1 | 0 | 1 |
| 2017 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Fluoxetine" by people in Profiles.
-
Relationships between circadian measures, depression, and response to antidepressant treatment: A preliminary investigation. Psychiatry Res. 2017 06; 252:262-269.
-
Early and late-onset effect of chronic stress on vascular function in mice: a possible model of the impact of depression on vascular disease in aging. Am J Geriatr Psychiatry. 2011 Apr; 19(4):335-46.
-
Prospective trial of efficacy and safety of ondansetron and fluoxetine in patients with obstructive sleep apnea syndrome. Sleep. 2010 Jul; 33(7):982-9.
-
Assessing rates and predictors of tachyphylaxis during the prevention of recurrent episodes of depression with venlafaxine ER for two years (PREVENT) study. Psychopharmacol Bull. 2009; 42(3):5-20.
-
Examination of the decline in symptoms of anxiety and depression in generalized anxiety disorder: impact of anxiety sensitivity on response to pharmacotherapy. Depress Anxiety. 2008; 25(2):167-71.
-
The Prevention of Recurrent Episodes of Depression with Venlafaxine for Two Years (PREVENT) study: outcomes from the acute and continuation phases. Biol Psychiatry. 2007 Dec 15; 62(12):1371-9.
-
The Prevention of Recurrent Episodes of Depression with Venlafaxine for Two Years (PREVENT) Study: Outcomes from the 2-year and combined maintenance phases. J Clin Psychiatry. 2007 Aug; 68(8):1246-56.
-
Preliminary support for gender differences in response to fluoxetine for generalized anxiety disorder. Depress Anxiety. 2006; 23(6):373-6.
-
A Double-blind, randomized trial of St John's wort, fluoxetine, and placebo in major depressive disorder. J Clin Psychopharmacol. 2005 Oct; 25(5):441-7.
-
Olanzapine augmentation of fluoxetine for refractory generalized anxiety disorder: a placebo controlled study. Biol Psychiatry. 2006 Feb 01; 59(3):211-5.